Summary This latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Drugs In Development, 2021, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape.
Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Wilson Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Wilson Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Wilson Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Wilson Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 2, 5 and 4 respectively.
Wilson Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Wilson Disease (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Wilson Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Wilson Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Wilson Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Wilson Disease (Genetic Disorders)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Wilson Disease (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Wilson Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
280 pages •
By Global Industry Analysts
• Feb 2022
Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares -Market presence across multiple geographies - Strong/Active/Niche/Trivial -Online interactive peer-to-peer collaborative bespoke updates -Access to our digital archives and MarketGlass...
200 pages •
By The Business Research Company
• May 2022
Major players in the anatomical pathology equipment and consumables market are Epridea, F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Sakura Finetek, Agilent Technologies, Danaher Corporation, Bio SB, BioGenex Laboratories, and Quest Diagnostics Incorporated. The global anatomic pathology equipment and consumables...
175 pages •
By The Business Research Company
• May 2022
Major players in the critical illness market are China Life Insurance, Allianz, Ping An Insurance, Aviva, Legal & General, China Pacific Insurance, Prudential plc, New China Life Insurance, Aegon, and AXA. The global critical illness insurance market is expected to grow from $185.53 billion in 2021 to $215.49 billion in 2022 at a compound...
The global alopecia treatment market reached a value of US$ 3 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 3.9 Billion by 2027, exhibiting a CAGR of 4.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as...
Deep brain stimulation (DBS) therapies target a growing number of existing indications, including movement disorders and neuropsychiatric conditions, and newer areas such as lifestyle disorders, including diabetes and obesity.This will allow more patients to benefit from the therapy. According to the WHO, neurological diseases currently...
The global intravenous solutions market reached a value of US$ 13.2 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 18.6 Billion by 2027, exhibiting a CAGR of 5.96% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence...
The global surrogacy market reached a value of US$ 161.83 Million in 2021. Looking forward, the analyst expects the market to reach a value of US$ 240.56 Million by 2027, exhibiting a CAGR of 6.62% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect...
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 184.108.40.206) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 220.127.116.11) - Janus kinase 2 is a non-receptor tyrosine...
The frozen tissues samples market is projected to reach US$ 105,045.91 Thousand by 2028 from US$ 44,399.07 Thousand in 2021; it is estimated to grow at a CAGR of 13.1% during 2021-2028. The report highlights trends prevailing in the market and the factors driving it.The growth of the frozen tissues samples market is attributed to the...
Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs in Development by Stages, Target, MoA,...
Digestive System Disorder
Medical Technology Density
Prescription Drug Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.